SCHEMBL7704966

SCHEMBL7704966

Cc1cccc(CN(Cc2ccc3c(c2)NC(=S)C(C)O3)C(=O)OC(C)(C)C)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.37
HSD17B10 Q99714 4/20 0.35
ALOX15 P16050 3/20 0.35
PARP1 P09874 2/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 3/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
THRB P10828 1/20 0.32
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ALOX12 P18054 1/20 0.31
MAPK1 P28482 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6310115 0.92 PARP1 (0.37) TP53HSD17B10ALOX15PARP1USP2
SCHEMBL7710782 0.90 PARP1 (0.44) TP53HSD17B10ALOX15PARP1USP2
SCHEMBL7711006 0.89 PARP1 (0.36) TP53HSD17B10ALOX15PARP1USP2
SCHEMBL6309617 0.87 HDAC1 (0.43) HSD17B10ALOX15PARP1HDAC3HDAC1
SCHEMBL7704907 0.87 HSD17B10 (0.38) TP53HSD17B10ALOX15PARP1USP2
SCHEMBL7704945 0.87 HDAC3 (0.44) HSD17B10ALOX15PARP1HDAC3HDAC1
SCHEMBL7704942 0.87 ALDH1A1 (0.37) TP53HSD17B10ALOX15PARP1HDAC3
SCHEMBL6309909 0.86 HSD17B10 (0.33) TP53HSD17B10ALOX15PARP1TSHR
SCHEMBL7708255 0.86 RIPK1 (0.36) HSD17B10ALOX15PARP1TSHRHDAC3
SCHEMBL7712797 0.86 RIPK1 (0.36) TP53HSD17B10ALOX15PARP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed